story of the week
MRI-Guided Optimisation of Neoadjuvant Chemotherapy Duration in Patients With Stage II to III HER2-Positive Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II-III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study
Lancet Oncol 2024 May 01;25(5)603-613, A van der Voort, FM Louis, MS van Ramshorst, R Kessels, IA Mandjes, I Kemper, MJ Agterof, WA van der Steeg, JB Heijns, ML van Bekkum, EJ Siemerink, PM Kuijer, A Scholten, J Wesseling, MTFD Vrancken Peeters, RM Mann, GS SonkeFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.